Abstract
Chen et al. show that candesartan (Cand) displays an antioxidant action independent of angiotensin type 1 receptor (AT1R) blockade that translates into a superior renoprotection of chronic renal inflammation. The peculiarity of Cand in combining AT1R-blocking activity and an antioxidant action could have important theoretical implications for therapy.
Original language | English |
---|---|
Pages (from-to) | 1112-1114 |
Number of pages | 3 |
Journal | Kidney International |
Volume | 74 |
Issue number | 9 |
DOIs | |
Publication status | Published - Nov 2008 |
ASJC Scopus subject areas
- Nephrology